Life Sciences Connect

Europe faces substantial challenges in continuing to deliver high-quality healthcare services to its citizens. With growing populations, rigid financing models and rising health inequalities, the conventional, reactive 'sick care' model needs to move to a more proactive, preventative and participatory model of care. Without this transition, by 2040, European healthcare services will face being overwhelmed and unaffordable with diminished access, adversely affecting citizens' health and productivity. Listen to episode 28 of the Life Sciences Connect Podcast to hear our guests dive into the most crucial questions from The Future of Health in Europe report.

In episode 27 of the Life Sciences Connect Podcast, we speak to the authors of the Time to Change report and discuss the current state of the UK healthcare workforce, touching on topics including pay, diversity, work-life balance, and training.  During our conversation, we explore the unrelenting challenges facing the UK's healthcare workforce and share actionable, evidence-based solutions to help improve staff wellbeing, recruitment, and retention at a local level.

In Episode 26, our panel of industry experts dive into the key trends and challenges facing the consumer health industry. This is one not to miss. With increased access to information, greater levels of choice and improved functionality of products and technology, consumers are increasingly taking a more proactive role in managing their own health. Tune in for our expert panel's views on the future of the industry.

Tune in to the latest episode of the Life Sciences Connect podcast, where you will find Sara Siegel's fireside chat about all things Global Healthcare Episode 25 welcomes the new Global Head of Health and previous guest, Sara Siegel who discusses with Karen the various challenges impacting global healthcare systems today, their hopes and ambitions for the future.

Karen and the team explore the findings from the Future of Diagnostic Series   Episode 24 podcast explores some of the themes highlighted in our two reports on the future of diagnostics and specifically how the adoption of innovation and new models of service delivery are transforming diagnostic imaging. 

Listen to episode twenty-three to hear Karen, and our guests dissect the findings from the latest annual R&D ROI Report which launched last month. This report has provided insights into the state of biopharma R&D since 2010. We have expanded the analysis over time and our data set now covers the top 20 pharma companies by R&D spend

In episode twenty-two, we explore the challenges facing UK government and public services. Tune in as our experts discuss the issues currently facing health and social care, from unsustainable levels of funding to longstanding pressures on the workforce. Join Karen Taylor, Ed Roddis and Emma Horrell as they dissect the findings from the latest State of the State report to bring you a view of the state from the people who use and the people who run it: State of the State

On this episode of Life Sciences Connect podcast, we bring the discussion of emission reduction to the forefront. Hear our guest discuss further: James Gregson – UK's Life Sciences & Healthcare industry leader At the start of October we launched our report: Embedding environmental sustainability into pharma's DNA. In this episode of we explore the pressing challenges facing pharma in achieving ambitious environmental sustainability targets and evaluate ways of making progress through easy wins across the value chain, culture changes and new investment. These quick wins can provide the license to make transformative, fundamental changes that are necessary to achieve pharma's targets. Listen to hear more on this topic.

On this episode of Life Sciences Connect podcast, we discuss these issues further with our panel of experts: Andy Flockhart, UK MedTech Leader Guido Baechler, CEO of Mainz Biomed And of course, our host, Karen Taylor, Research Director, Centre for Health Solutions, Deloitte Diagnostics play a pivotal role across the entire healthcare continuum from screening, detection and prognosis to patient stratification and condition monitoring While diagnostics have always been one of the foundations of healthcare, advances in science and technology mean they are now well positioned to play a key role in revolutionising healthcare. Driving the need for innovation are growing and ageing populations, the increasing prevalence of non-communicable diseases and chronic conditions, workforce shortages and an increasingly knowledgeable and empowered consumer base Listen to hear more on this topic.

Episode 19 of the Life Sciences Connect podcast sheds light on the important topic of Health equity and dives into discussions around what this really means, what businesses can do to improve this, how diversity groups are affected and much more. To learn more about health equity and other important issues facing public health in the UK, explore out Future of Public Health Series

Listen to episode 18 of the Life Sciences Connect podcast where we talk to specialists about Hospital Activation, how we are breaking from the traditional approach and what the future holds.

Listen to episode 17 of the Life Sciences Connect podcast here where we continue with the Future of Public Health series and dive further into the report- Evaluating the role of employers in reducing the public health gap: Improving the health and productivity of employees.

In episode sixteen of the Life Science Connect podcast, we dive into the conversation around our fourth report in our Future of Public Health series; Negating the gap - Preventing ill health and promoting healthy behaviours. Joining our host Karen Taylor, Research Director of the Deloitte UK Centre for Health Solutions, is Dr Karen Kirkham, Chief Medical Officer and Lead Partner for Integration in Deloitte's Health and Social Care team and Sara Siegel, Deloitte's UK and EMEA Head of Healthcare as we examine the crucial role of public health in health protection, ill-health prevention and in promoting healthy behaviours. Despite a wealth of evidence that investing in prevention is fundamental to a resilient and sustainable health system, the UK, like most other countries, spends less than five per cent of healthcare funding on preventative services. Listen to hear more about this debate and see what some of the experts have to say on this topic

In episode fifteen of the Life Science Connect podcast, we dive into the conversation around our annual R&D Measuring the return from pharmaceutical innovation series report. This report analyses the projected return on investment that biopharma companies can expect to earn from their late-stage pipelines. 

In episode fourteen of the Life Science Connect podcast, we dive into the conversation around planetary health and sustainability in healthcare. Following COP26, it is important that we discuss points around the fundamental risk of climate change and how it impacts our health as well as healthcare delivery and its impact on climate. On this episode of Life Science's Connect podcast, we discuss these issues further with Deloitte experts on the panel, including: James Gregson: Managing Partner, UK Life Sciences and Healthcare leader and Global Life Sciences and Healthcare ESG leader, Deloitte Lisa Dittmar: Manager, Deloitte's Net Zero Transformation team, Monitor Deloitte Will Saddlington: Director in the consulting practice, Deloitte And of course, our host, Karen Taylor, Head of The Centre for Health Solutions, Deloitte Our recent future of public health report series includes a report titled “Bridging the gap: Protecting the nation from public health threats”, where we highlight the issues of climate change and the fundamental threat it poses health as well as how healthcare delivery itself impacts the environment. Visit the Life Sciences Connect Podcast homepage to discover more episodes.

In our thirteenth episode of the Life Science Connect podcast series, we discuss the findings from The Future of Public Health Series, covered in the overview report: Narrowing the gap: A fairer and more sustainable future for public health. This first instalment of the series summarises the key takeaways from our research of the challenges pre-pandemic, the impact of COVID-19 and the implications for the future for public health systems in the UK.   Joining our host Karen Taylor, Research Director of the Deloitte UK Centre for Health Solutions, is Karen Kirkham, Chief Medical Officer and Lead Partner for Integration in Deloitte's Health and Social Care team and Cosima Pettinicchio, Director in Consulting in the Health and Social Care team. 

In our twelfth episode of Life Sciences Connect, our host, Karen Taylor, the Research Director of the Centre for Health Solutions talks to Hanno Ronte, Partner at Monitor Deloitte about consumer research conducted this year on trust in the pharmaceutical industry and explores how COVID-19 has impacted trust, the perception and what role digital can play.  

In our eleventh episode of Life Sciences Connect, we talk to Karen Taylor, Research Director of the Deloitte Centre for Health Solutions who is joined by Thomas Croisier, Consulting Partner, Deloitte France; Deborshi Dutt, Consulting Partner, Deloitte UK and Kristina Schapiro, Consulting Director, Deloitte UK to discuss how companies can use AI to improve drug launches and their commercial models.   Visit our Life Sciences Connect Podcast homepage to discover more episodes - https://www2.deloitte.com/uk/en/pages/life-sciences-and-healthcare/articles/life-sciences-connect.html    

In our tenth episode of Life Sciences Connect, we talk to Karen Taylor, Research Director of the Deloitte Centre for Health Solutions who is joined by Naveed Panjwani, Director, Consulting, Deloitte and Kevin Dondarski, Senior Manager, Consulting, Deloitte US to discuss research and development. Visit our Life Sciences Connect Podcast homepage to discover more episodes - https://www2.deloitte.com/uk/en/pages/life-sciences-and-healthcare/articles/life-sciences-connect.html      

Our ninth episode of Life Sciences Connect series explores the key trends for the Medtech industry including the rise in consumer organisations entering the space, the evolution from product to service, the changing regulatory landscape, and the acceleration of MedTech in healthcare because of COVID-19. Visit our Life Sciences Connect Podcast homepage to discover more episodes.        

James Gregson, our newly appointed UK Life Sciences and Healthcare leader, joins our episode host Samrina Bhatti, to share his thoughts  on what's next for the industry. James talks about his  leadershipstyle and what makes a good leader as well as his views on digital transformation,collaboration  and developing talent in the Life Sciences and Healthcare industry. Visit our Life Sciences Connect Podcast homepage to discover more episodes.      

What lies ahead for patients, your organisation and your workforce? In this podcast, we explore our predictions for the life sciences and health care industry in 2025, how the pandemic has accelerated industry trends and what this means for you. Our host Karen Taylor, who leads Deloitte Centre for Health Solutions, speaks to  Hanno Ronte, Life Sciences and Healthcare leader Monitor Deloitte, Shivani Maitra, in our Future of Work team, and Sara Siegel, Public Sector Healthcare lead. This episode explores: Key features of the life sciences and healthcare industry in the next 5 years How the legacy of the pandemic has accelerated the  future for all stakeholders in the health ecosystem  The role of collaboration, technology and new skills and talent.      

C-suite leaders in pharmaceutical companies increasingly view Real World Evidence (RWE) as strategically important. RWE enables R&D organisations to prioritise their pipeline investments more effectively, better understand underlying causes of disease and identify opportunities for indication expansion and business development. In the sixth episode of Life Sciences Connect, we explore the role of Real World Evidence in providing insights into existing diagnostic and treatment pathways, identifying unmet need and demonstrating the clinical and economic impact of interventions within the healthcare system. This episode is led by our host Karen Taylor. Karen is joined by Meri Petrovsca, the Knowledge Management Director at AstraZeneca and Seb Burnett, the General Manager of ConvergeHEALTH by Deloitte Europe. This episode explores: The impact of RWE on biopharma companies Implementing knowledge management to maximise Real World Data (RWD) The role of skills and talent in maximising value from RWD and the challenges the industry faces in accessing such talent  

Healthcare systems across Europe face rising pressures – particularly the increasing healthcare needs due to growing and ageing populations, multi-morbidity, and public expectations of more personalised and convenient services. Many clinicians are struggling to cope with increasing workloads, and the gap between the supply of resources and the demand for healthcare is widening. Consequently, most countries are looking to digital transformation to close this gap but progress has largely been slow, and the digital maturity of providers, both within and between countries, varying widely. While COVID-19 has accelerated technology adoption and all countries can point to examples of good practice, there is scope for lessons to be learned more widely and for many of the alliances and partnerships that have been established over the past few months to become a driver of new models of outcome based care and shape a more predictive, preventative, personalised and participatory future.     Our survey respondents of some 1800 clinicians across seven countries identified that the top challenges in implementing digital technologies were bureaucracy in healthcare, the cost of technology and finding the right technologies. Despite the challenges that lie ahead, our surveyed clinicians felt increasingly positive about the adoption of digital technologies. In the fifth episode of Life Sciences Connect, we explore the challenges facing digital transformation in European healthcare, how things have been changing as a result of COVID-19 and how we should proceed into the future.    

The Biotech sector is a key player in driving biopharma innovation and developing ground-breaking treatments for patients. Supporting the growth of this sector is vital to ensure that R&D efforts continue, both now and in the future. However, like most industries, this sector faces a complex set of challenges. Over the past six months, the biotech sector has rapidly pivoted to respond to the challenge of the COVID-19 pandemic. Companies have grappled with this new reality by adapting to a new way of working and by forging new partnerships across the sector. In the next six months, companies will need to navigate the challenges associated with Brexit including planning for possible workforce related issues and a possible new regulatory environment. In the fourth episode of Life Sciences Connect, we explore the challenges and opportunities facing the Biotech Industry.  

The COVID-19 pandemic has brought the Life Sciences Industry to an inflection point. It has exposed the limitations of traditional linear supply chain models, highlighted the need for sustainability and accelerated the move towards digital transformation. Will the COVID-19 pandemic act as a catalyst for biopharma companies to recognise their vulnerabilities and accelerate the digital transformation of their global supply chain models? In the third episode of Life Sciences Connect, we explore the digital transformation of the biopharma supply chain and adoption of AI powered technology.  

In the second episode of Life Sciences Connect, we explore how the COVID-19 pandemic has accelerated the move towards the Future of Health, where technology and data enable health care that is more personalised, predictive, preventative and participatory.  

Life Sciences Connect is the brand new podcast brought to you by the Deloitte Centre for Health Solution. Each month, we will connect with industry experts and leaders from the Biotech, Pharmaceutical and Medical Devices industries to discuss how key trends, explored in our research reports, are charting a new, sustainable future for the Life Sciences Industry.  

For our first episode, we explore the use of AI technology in clinical trials and how the COVID-19 pandemic is promoting the use of advanced technologies within the biopharma industry. This episode is led by our host Karen Taylor. Karen is joined by Fiona Maini, Principal Global Science and Compliance at Medidata, and Fareed Melham, Head of Acorn AI Labs at Medidata Solutions. This episode covers: How AI technology is currently being used in clinical trials How regulators are embracing AI in clinical development How regulators are changing their approach in response to COVID-19, including in the acceptance of AI technologies and RWE strategies.